GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » 5-Day RSI

Cormedix (Cormedix) 5-Day RSI : 50.73 (As of Apr. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cormedix 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-29), Cormedix's 5-Day RSI is 50.73.

The industry rank for Cormedix's 5-Day RSI or its related term are showing as below:

CRMD's 5-Day RSI is ranked worse than
59.41% of 1572 companies
in the Biotechnology industry
Industry Median: 45.555 vs CRMD: 50.73

Competitive Comparison of Cormedix's 5-Day RSI

For the Biotechnology subindustry, Cormedix's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Cormedix's 5-Day RSI falls into.



Cormedix  (NAS:CRMD) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cormedix  (NAS:CRMD) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Cormedix 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Cormedix's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (Cormedix) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry officer: Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco director, officer: Chief Executive Officer 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan director C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa director MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart director 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione director ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David officer: EVP, Chief Financial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson officer: EVP, Head of Clinical Ops. 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel officer: EVP, Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan director 44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz director SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan director 700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L. officer: Exec VP of Tech Operations C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch director, officer: Chief Executive Officer 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921